Latest News
Two new pressure-lowering glaucoma medications have been approved by the FDA and are becoming available in the United States. Each is unique, and one is the first in a new class of drugs.
Different macular disorders could one day be stopped by treatments aimed at some of the earliest cellular changes that these diseases have in common. Read more about this exciting research, find out why bacteria in our guts can affect our risk of developing age-related macular degeneration (AMD), and learn about a clinical trial that will help determine if alpha lipoic acid can slow down the growth of the advanced form of dry AMD, all in the spring 2018 edition of Macular Degeneration Research News.
The winter 2018 edition of the National Glaucoma Research Report has information on a BrightFocus research grant that is leading to a new understanding of glaucoma, an article outlining the connection between diabetes and glaucoma, helpful facts about how clinical trials work, and much more.
Learn about a major study that sheds new light into the causes of Alzheimer's, an innovative Alzheimer's project that is (literally) out of this world, helpful tips for when Alzheimer's affects sleep, a Q&A on clinical trials with Dr. Mario Cornacchione, and more in the winter edition of the Alzheimer's Disease Research newsletter.
BrightFocus Foundation, a nonprofit and premier source of research funding to defeat Alzheimer’s, macular degeneration, and glaucoma, today was acknowledged as the catalyst behind a major advance in drug development for Alzheimer’s disease.
A panel of leading researchers and policy experts has released five key recommendations for public and private sector leaders to better support people with dementia living in their own home.
“BrightFocus Foundation lauds today’s historic announcement by Bill Gates of his $50 million investment in the Dementia Discovery Fund. A charitable act of this magnitude is a profound example of the courage and the power of philanthropy to tackle society’s most pressing challenges."